Clinical Trials Browser

Phase 2/3 × Urinary Bladder Neoplasms × Genitourinary × Clear all

NCT06225596 2026-04-15

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Phase 2/3 Active not recruiting

Urinary Bladder Neoplasms

NCT07106762 2026-04-15

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Phase 2/3 Recruiting

Urinary Bladder Neoplasms

NCT07129993 2026-03-19

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2/3 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06851663 2025-12-08

Trop2-targeted immunoPET Imaging of Solid Tumors

Phase 2/3 Recruiting

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05786716 2025-12-02

DETERMINE

Phase 2/3 Recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther hematologic neoplasmThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT03022825 2025-10-16

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Phase 2/3 Active not recruiting

190 enrolled 1 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06537154 2025-07-30

NEO-BLAST

Phase 2/3 Recruiting

Urinary Bladder Neoplasms

NCT01869413 2022-10-04

TACT

Phase 2/3 Completed

Urinary Bladder Neoplasms

NCT01438112 2021-04-14

BOND

Phase 2/3 Terminated

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

NCT02355886 2019-06-04

Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy

Phase 2/3 Completed

25 enrolled 8 charts

Urinary Bladder Neoplasms

NCT01668459 2018-12-04

CabB1

Phase 2/3 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT03427034 2018-02-09

ABSEIL

Phase 2/3 Unknown

Urinary Bladder Neoplasms, Hematuria, Recurrence

NCT01475266 2017-03-29

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Phase 2/3 Terminated

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT00406068 2016-07-28

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Phase 2/3 Completed

Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Mycobacterium Infections, Neoplasm Recurrence, Local

NCT00389155 2015-12-07

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

Phase 2/3 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT01316874 2015-06-12

Bladder Cancer

Phase 2/3 Completed

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT00949455 2015-04-15

LaMB

Phase 2/3 Unknown

Urinary Bladder Neoplasms

NCT00014274 2013-06-12

Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium

Phase 2/3 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00006124 2013-02-13

Celecoxib in Treating Patients With Bladder Cancer

Phase 2/3 Completed

Urinary Bladder Neoplasms

NCT00330707 2011-03-04

Combined Use of BCG and Interferon Alpha in Bladder Cancer

Phase 2/3 Completed

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms